BiotechTube

Eldecalcitol soft capsules

Pre-clinicalUNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopausal Osteoporosis

Conditions

Postmenopausal Osteoporosis

Trial Timeline

Aug 1, 2022 → Jan 31, 2025

NCT ID
NCT05433207

About Eldecalcitol soft capsules

Eldecalcitol soft capsules is a pre-clinical stage product being developed by Chugai Pharmaceutical for Postmenopausal Osteoporosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT05433207. Target conditions include Postmenopausal Osteoporosis.

What happened to similar drugs?

20 of 20 similar drugs in Postmenopausal Osteoporosis were approved

Approved (20) Terminated (1) Active (0)
✅Teriparatide + Strontium ranelateEli LillyApproved
✅teriparatideEli LillyApproved
✅Teriparatide + RaloxifeneEli LillyApproved
✅teriparatide + aldrenodate + raloxifeneEli LillyApproved
✅teriparatide + raloxifene HCl + placeboEli LillyApproved
✅Teriparatide + Risedronate + Placebo + Calcium + Vitamin DEli LillyApproved
✅LetrozoleNovartisApproved

Hype Score Breakdown

Clinical
3
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05433207Pre-clinicalUNKNOWN

Competing Products

20 competing products in Postmenopausal Osteoporosis

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
40
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
40
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
CT-P41 + US-licensed ProliaCelltrionPhase 3
40
LetrozoleChugai PharmaceuticalPhase 2
35
LetrozoleChugai PharmaceuticalPhase 2
35
LetrozoleChugai PharmaceuticalPhase 2
35
menatetranone + alfacalcidolEisaiPhase 3
40
teriparatide + raloxifene + placeboEli LillyPhase 3
40
Teriparatide + Strontium ranelateEli LillyApproved
43
teriparatideEli LillyApproved
43
LY333334 + PlaceboEli LillyPhase 1
29
Teriparatide + RaloxifeneEli LillyApproved
43
teriparatide + aldrenodate + raloxifeneEli LillyApproved
43
LAE102 SC + Placebo SC + LAE102 IV + Placebo IVEli LillyPhase 1
29
BlosozumabEli LillyPhase 1
29
BlosozumabEli LillyPhase 1
21
Arzoxifene + RaloxifeneEli LillyPhase 3
40
teriparatide + raloxifene HCl + placeboEli LillyApproved
43
Raloxifene HCL + Raloxifene HCL + PlaceboEli LillyPhase 3
40